Skip to main content

Good test results for Christmas - Pirfenidone four month report

The test results are in. I haven't been able to blog about them until now because the network at NIH has been up and down this evening. The good news is I did read my pulmonary function tests correctly. My FVC (forced vital capacity) was 91! This is up from 81 four months ago when I started the Pirfenidone trial.

Dr. Gahl gave me a rather lengthy explanation about how I shouldn't get too worked up. This isn't really a huge change because none of the other numbers changed much etc. Yep, I know that. At the same time, I'm grateful, giving thanks to God, and hey, I don't have to go into Christmas with bad news. I can CELEBRATE! Dr. Gahl cracks me up. What doc, I look too happy to you? Just let me enjoy this little moment. Grin! My DLCO did fall a bit, from 63 to 60, but that's still within the margin of error. My oxygen saturation also did fall on the six-minute walk test to 94, which isn't good but is about the same as four months ago. I was, however, able to walk 47 meters further than last time.

The funny spot on my lung, however, is pulmonary fibrosis. I'm not too upset about that as that's what we thought four months ago. The good news is this horrible, horrible cold I've had for five weeks doesn't appear to have done any further damage. The CT scan isn't really changed from last time. It's just a matter of the realization that this isn't maybe just an infection - it's pulmonary fibrosis and that isn't ever going to go away.

There was one other person here at NIH that was also admitted to the drug trial this week. That was exciting too. It's just one more step closer to the next step to the cure! It's one more step closer to making sure that this drug becomes available to everyone that needs it.

Comments

Popular posts from this blog

Ratner's Cheesecake

Here's another recipe from Toby! Thanks Toby......and I'll get the others posted soon! Ratner's Cheesecake and plain cookies Ratner's was a Jewish dairy restaurant in the lower East Side of Manhattan. This recipe, from my disintegrating, no longer in print Ratner's cookbook, is the closest I've ever gotten to reproducing the rich, heavy cheesecake my mother made when I was a kid. It's worth the time it takes to prepare and every last calorie. Dough Can be prepared in advance. Makes enough for two cakes. Can be frozen or used to make cookies – see recipe below. 1 cup sugar 1 teaspoon vanilla extract 1 cup shortening 1 teaspoon lemon extract 1 cup butter 2 eggs 3 cups sifted cake flour ½ teaspoon salt 2 cups all purpose flour 1 teaspoon baking powder 1. In a bowl, combine all ingredients with hands. Refrigerate 3 -4 hours, or preferably overnight. Filling (for

The next generation with Hermansky-Pudlak Syndrome

I'm so behind on posting about the trip to Puerto Rico. Since the episode of Mystery Diagnosis on Hermansky-Pudlak Syndrome ran right after we got home, it's been a little busy. These, however, are my favorite pictures from Puerto Rico. I know, not pretty senery etc - but these little guys and gals inspire me. They are the next generation of folks with HPS, and if we keep up the hard work, they will live better lives because of it. They motivate me.

Some good news about Pirfenidone

Below is a press release from Intermune, the company that makes Pirfenidone. They have essentially reviewed the various clinical trials going on, and decided that Pirfenidone is safe and well tolerated. That would pretty much go along with what we've observed in the HPS community as well. We have a few folks that have been on the drug since the late 90s and continue to do well. Of course, as a journalist, I do have to say consider the source - but at the same time, as someone in a Pirfenidone trial, it's good to know. Results of Comprehensive Safety Analysis of pirfenidone In IPF Patients Presented At European Respiratory Meeting - Analysis shows safety and tolerability of pirfenidone across four clinical trials - VIENNA, Sept. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN ) today announced that the results of a comprehensive review of safety data from four clinical studies were presented at the 2009 European Respiratory Society Annual Congress in Vienna, Austria